NEW YORK (GenomeWeb) – Academic institutions and molecular diagnostic companies are increasingly developing tests that run on next-generation sequencing platforms, but reimbursement for such tests can often seem arbitrary — varying depending on the specific insurer, by the test developer, the indication for the test, and even on an individual case-by-case basis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.